Mutagenicity of tamoxifen DNA adducts in human endometrial cells and in silico prediction of p53 mutation hotspots

Nucleic Acids Research

Volumn 36, Issue 18, 2008, Pages 5933-5945

  Liapis, Evagelos ^a   Mcluckie, Keith E E ^a   Lewis, Paul D ^b   Farmer, Peter B ^a   Brown, Karen ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b SINGLETON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ALANINE; CYSTEINE; GENE PRODUCT; GLYCINE; PROTEIN P53; PROTEIN SUPF; TAMOXIFEN; THREONINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; CANCER GROWTH; CANCER RISK; CODON; CONTROLLED STUDY; DNA DAMAGE; DNA METHYLATION; DNA MODIFICATION; DNA SEQUENCE; DOSE RESPONSE; ENDOMETRIUM CELL; ESCHERICHIA COLI; GENE MUTATION; GENETIC SCREENING; GENOME ANALYSIS; HUMAN; HUMAN CELL; MUTAGENICITY; MUTATION RATE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; SEQUENCE ANALYSIS;

ALGORITHMS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CELL LINE; DNA ADDUCTS; DNA MUTATIONAL ANALYSIS; ENDOMETRIUM; ESTROGEN ANTAGONISTS; FEMALE; GENES, P53; GENES, SUPPRESSOR; HUMANS; MUTAGENESIS; RATS; RNA, TRANSFER; TAMOXIFEN;

ESCHERICHIA COLI;

EID: 54549089028     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkn586     Document Type: Article

References (66)

1. Cuzick,J., Powles,T., Veronesi,U., Forbes,J., Edwards,R., Ashley,S. and Boyle,P. (2003) Overview of the main outcomes in breastcancer prevention trials. Lancet, 361, 296-300.
2. Fomander,T., Rutqvist,L.E., Cedermark,B., Skoog,L., Theve,T., Askergren,J., Rutqvist,L.E., Glas,U., Silfversward,C., Somell,A. et al. (1989) Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet, 1, 117-120.
3. Fisher,B., Costantino,J.P., Redmond,C.K., Fisher,E.R., Wickerham,D.L. and Cronin,W.M. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl Cancer Inst., 86, 527-537.
4. Brown,K. (2000) Breast cancer chemoprevention: Risk-benefit effects of the antioestrogen tamoxifen. Expert Opin. Drug Saf., 1, 253-267.
5. Phillips,D.H., Carmichael,P.L., Hewer,A., Cole,K.J., Hardcastle,I.R., Poon,G.K., Keough,A. and Strain,A.J. (1996) Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA-binding products: Comparisons between human, rat and mouse hepatocytes. Carcinogenesis, 17 89-94.
6. Shibutani,S., Dasaradhi,L., Terashima,I., Banoglu,E. and Duffel,M.W. (1998) α-hydroxytamoxifen is a substrate of hydroxysteroid. (alcohol) sulf6transferase, resulting in tamoxifen DNA adducts. Cancer Res., 58, 647-653.
7. Davis,W., Venitt,S. and Phillips,D.H. (1998) The metabolic activation of tamoxifen and a-hydroxytamoxifen to DNA-binding species in rat hepatocytes proceeds via sulphation. Carcinogenesis, 19, 861-866.
8. Poon,G.K., Walter,B., Lonning,P.E., Horton,M.N. and McCague,R. (1995) Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab. Dispos., 23, 377-382.
9. Singh,M.N., Stringfellow,H.F., Walsh,M.J., Ashton,K.M., Phillips,D.H., Martin-Hirsch,P.L. and Martin,F.L. (2007) Potential for phase I/II metabolism of tamoxifen in human endometrium: Expression of CYP3A4 and SULT2A1. Mutagenesis, 22, 450.
10. Umemoto,A., Monden,Y., Lin,C.X., Momen,A., Ueyama,Y., Komaki,K., Laxmi,Y.R.S. and Shibutani,S. (2004) Determination of tamoxifen-DNA adducts in leukocytes from breast cancer patients treated with tamoxifen. Chem. Res. Toxicol., 17, 1577-1583.
11. Martin,E.A., Brown,K., Gaskell,M., Al-Azzawi,F., Garner,R.C., Boocock,D.J., Mattock,E., Pring,D.W., Dingley,K., Turteltaub,K.W. et al. (2003) Tamoxifen DNA damage detected in human endometriurn using accelerator mass spectrometry. Cancer Res., 63, 8461-8465.
12. Shibutani,S., Suzuki,N., Terashima,I., Sugarman,S.M., Grollman,A.P. and Pearl,M.L. (1999) Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem. Res. Toxicol., 12, 646-653.
13. Shibutani,S., Ravindernath,A., Suzuki,N., Terashima,I., Sugarman,S.M., Grollman,A.P. and Pearl,M.L. (2000) Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis, 21, 1461-1467.
14. 14C]-labeled therapeutic dose. Cancer Res., 67, 6995-7002.
15. Carmichael,P.L., Ugwumadu,A.H., Neven,P., Hewer,A.J., Poon,Q.K. and Philhps,D.H. (1996) Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res., 56, 1475-1479.
16. 32P-postlabeling analyses of tamoxifen-DNA adducts in humans. J. Natl Cancer Inst., 1099-1104.
17. Marques,M.M. and Beland,F.A. (1997) Identification of tamoxifen-DNA adducts formed by 4-hydroxytamoxifen quinone methide. Carcinogenesis 18, 1949-1954.
18. 32p∝st-labelled DNA adducts by the development of a novel automated on-line solid-phase extraction HPLC method. Carcinogenesis, 19 1061-1069.
19. 2-deoxyguanosinyl tamoxifen. Biochemistry, 36, 13010-13017.
20. 2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res., 59, 2091-2195.
21. McLuckie,K.I.E., Routledge,M.N., Brown,K., Gaskell,M., Farmer,P.B., Roberts,G.C.K. and Martin,E.A. (2002) DNA adducts formed from 4-hydroxytamoxifen are more mutagenic than those formed by α-acetoxytamoxifen in a shuttle vector target gene replicated in human Ad293 cells. Biochemistry, 41, 8899-8906.
22. McLuckie,K.I.E., Crookston,R.J., Gaskell,M., Farmer,P.B., Routledge,M.N., Martin,E.A. and Brown,K. (2005) Mutation spectra induced by α-acetoxytamoxifen-DNA adducts in human DNA repair proficient and deficient (xeroderma pigmentosum complementation group A) cells. Biochemistry, 44, 8198-8205.
23. Pfeifer,G.P., You,Y.H. and Besaratinia,A. (2005) Mutations induced by ultraviolet light. Mutat. Res., 571, 19-31.
24. Grollman,A.P., Shibutani,S., Moriya,M., Miller,F., Wu,L., Moll,U., Suzuki,N., Fernandes,A., Rosenquist,T., Medverec,Z. et al. (2007) Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl Acad. Sci. USA, 104, 12129-12134.
25. Lunn,R.M., Zhang,Y.J., Wang,L.Y., Chen,C.J., Lee,P.H., Lee,C.S., Tsai,W.Y. and Santella,R.M. (1997) p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res., 57, 3471-3477.
26. Lewis,P.D. and Parry,J.M. (2004) In silico p53 mutation hotspots in lung cancer. Carcinogenesis, 25, 1099-1107.
27. Denissenko,M.F., Pao,A., Tang,M. and Pfeifer,G.P. (1996) Preferential formation of benzo [a]pyrene adducts at lung cancer mutational hotspots in p53. Science, 274, 430-432.
28. Osborne,M.R., Hewer,A., Hardcastle,I.R., Carmichael,P.L. and Phillips,D.H. (1996) Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res., 56, 66-71.
29. Brown,K., Heydon,R.T., Jukes,R., White,I.N. and Martin,E.A. (1999) Further characterization of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N, N didesmethyltamoxifen. Carcinogenesis, 20, 2011-2016.
30. Yoon,J.H., Smith,L.E., Feng,Z., Tang,M., Lee,C.S. and Pfeifer,G.P. (2001) Methylated CpG dinucleotides are the preferential targets for G-to-T transversion mutations induced by benzo [a]pyrene diol epoxide in mammalian cells: Similarities with the p53 mutation spectrum in smoking-associated lung cancers. Cancer Res., 61, 110-117.
31. You,Y.-H., Lee,D.-H., Yoon,J.-H., Nakajima,S., Yasui,A. and Pfeifer,G.P. (2001) Cyclobutane pyrimidine dimers are responsible for the vast majority of mutations induced by UVB irradiation in mammalian cells. J. Biol. Chem., 276, 44688-44694.
32. You,Y.-H. and Pfeifer,G.P. (2001) Similarities in sunlight-induced mutational spectra of CpG-methylated transgenes and the p53 gene in skin cancer point to an important role of 5-methylcytosine residues in solar UV mutagenesis. J. Mol. Biol., 105, 389-399.
33. Lewis,P.D., Manshian,B., Routledge,M.N., Scott,G.B. and Burns,P.A. (2008) Comparison of induced and cancer-associated mutational spectra using multivariate data analysis. Carcinogenesis, 29, 772-778.
34. Lee,D.-H. and Pfeifer,G.P. (2003) Deamination of 5-methylcytosines within cyclobutane pyrimidine dimers is an important component of UVB mutagenesis. J. Biol. Chem., 278, 10314-10321.
35. Yoon,J.H., Lee,C.S. and Pfeifer,G.P. (2003) Simulated sunlight and benzo [a]pyrene diol epoxide induced mutagenesis in the human p53 gene evaluated by the yeast functional assay: Lack of correspondence to tumor mutation spectra. Carcinogenesis, 24, 113-119.
36. Inga,A., Scott,G., Monti,P., Aprile,A., Abbondandolo,A., Burns,P.A. and Fronza,G. (1998) Ultraviolet-light induced p53 mutational spectrum in yeast is indistinguishable from p53 mutations in human skin cancer. Carcinogenesis, 19, 741-746.
37. Davies,R., Gant,T.W., Smith,L.L. and Styles,J.A. (1999) Tamoxifen induces G:C→T:A mutations in the cII gene in the liver of lambda/lacI transgenic rats but not at 5′-CpG'3′ dinucleotide sequences as found in the lacI transgene. Carcinogenesis, 20, 1351-1356.
38. Chen,T., Gamboa da Costa,G., Marques,M.M., Shelton,S.D., Beland,F.A. and Manjanatha,M.G. (2002) Mutations induced by α-hydroxytamoxifen in the lacI and cII genes of Big Blue transgenic rats. Carcinogenesis, 23, 1751-1757.
39. Gordenin,D.A. and Resnick,M.A. (1998) Yeast ARMs (DNA at-risk motifs) can reveal sources of genome instability. Mutat. Res., 400, 45-58.
40. Albertini,A.M., Hofer,M., Calos,M.P. and Miller,J.H. (1982) On the formation of spontaneous deletions: The importance of short sequence homologies in the generation of large deletions. Cell, 29, 319-328.
41. Shimizu,H., Yamaguchi,H., Ashizawa,Y., Kohno,Y., Asami,M., Kato,J. and Ikeda,H. (1997) Short-homology-independent illegitimate recombination in Escherichia coli: Distinct mechanism from short-homology-dependent illegitimate recombination. J. Mol. Biol., 266, 297-305.
42. Cariello,N.F., Piegorsch,W.W., Adams,W.T. and Skopek,T.R. (1994) Computer program for the analysis of mutational spectra: Application to p53 mutations. Carcinogenesis, 15, 2281-2285.
43. 2-dG adduct induced by a 5′-flanking 5-methyl-substituted cytosine in a (Me)CG double-stranded oligonucleotide sequence context. Chem. Res. Toxicol., 15, 438-444.
44. Weisenberger,D.J. and Romano,L.J. (1999) Cytosine methylation in a CpG sequence leads to enhanced reactivity with benzo [a]pyrene diol epox ide that correlates with a conformational change. J. Biol. Chem., 274, 23948-23955.
45. Bigger,C.A.H., St John,J., Yagi,H., Jerina,D.M. and Dipple,A. (1992) Mutagenic specificities of four stereoisomeric benzo[c]phenanthrene dihydrodiol epoxides. Proc. Natl Acad. Sci. USA, 89, 368-372.
46. Boldt,J., Mah,M.C.M., Wang,Y.C., Smith,B.A., Beland,F.A., Maher,V.M. and McCormick,J.J. (1991) Kinds of mutations found when a shuttle vector, containing adducts of 1,6-dinitropyrene replicates in human cells. Carcinogenesis, 12, 119-126.
47. Yang,J.L., Maher,V.M. and McCormick,J.J. (1987) Kinds of mutations formed when a shuttle vector containing adducts of (+/-)-7 beta, 8 alpha-dihydroxy-9 alpha, 10 α-epoxy-7,8,9, 10-tetrahydrobenzo [a]pyrene replicates in human cells. Proc. Natl Acad. Sci. USA 84, 3787-3791.
48. Routledge,M.N., McLuckie,K.I.E., Jones,G.D.D., Farmer,P.B. and Martin,E.A. (2001) Presence of benzo [a]pyrene diol epoxide adducts in target DNA leads to an increase in UV-induced DNA single strand breaks and supF gene mutations. Carcinogenesis, 22, 1231-1238.
49. Juedes,M.J. and Wogan,G.N. (1996) Peroxynitrite-induced mutation spectra of pSP189 following replication in bacteria and in human cells. Murat. Res., 349, 51-61.
50. Sikpi,M.O., Freedman,M.L., Ziobron,E.R., Upholt,W.B. and Lurie,A.G. (1991) Dependence of the mutation spectrum in a shuttle plasmid replicated in human lymphoblasts on dose of gamma radiation. Int. J. Radiat. Biol., 59, 1115-1126.
51. Keyse,S.M., Amaudruz,F. and Tyrrell,R.M. (1989) Determination of the spectrum of mutations induced by defined-wavelength solar UVB (313-nm) radiation in mammalian cells by use of a shuttle vector. Mol. Cell. Biol., 8, 5425-5431.
52. Yasui,M., Suzuki,N., Laxmi,Y.R. and Shibutani,S. (2006) Translesion synthesis past tamoxifen-derived DNA adducts by human DNA polymerases eta and kappa. Biochemistry, 45, 12167-12174.
53. Davies,R., Oreffo,V.I., Martin,E.A., Festing,M.F.W., White,I.N.H., Smith,L.L. and Styles,J.A. (1997) Tamoxifen causes gene mutations in the livers of lambda/lacI transgenic rats. Cancer Res., 57, 1288-1293.
54. Lewis,P.D., Harvey,J.S., Waters,E.M., Skibinski,D.O. and Parry,J.M. (2001) Spontaneous mutation spectra in supF: Comparative analysis of mammalian cell line base substitution spectra. Mutagenesis, 16 503-515.
55. Seo,K.Y., Jelinsky,S.A. and Loechler,E.L. (2000) Factors that influence the mutagenic patterns of DNA adducts from chemical carcinogens. Mutat. Res. Rev. Mutat. Res., 463, 215-246.
56. Soussi,T. and Lozano,G. (2006) Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat. Rev. Cancer, 6, 83-90.
57. Hollstein,M., Sidransky,D., Vogelstein,B. and Harris,C.C. (1991) p53 Mutations in human cancers. Science, 253, 49-53.
58. Prat,J., Gallardo,A., Cuatrecasas,M. and Catasús,L. (2007) Endometrial carcinoma: Pathology and genetics. Pathology, 39 72-87.
59. Ferguson,S.E., Soslow,R.A., Amsterdam,A. and Barakat,R.R. (2006) Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecol. Oncol., 101, 322-326.
60. Singh,M.N., Stringfellow,H.F., Paraskevaidis,E., Martin-Hirsch,P.L. and Martin,F.L. (2007) Tamoxifen: Important considerations of a multi-functional compound with organ-specific properties. Cancer Treat. Rev., 33, 91-100.
61. Dong,H., Bonala,R.R., Suzuki,N., Johnson,F., Grollman,A.P. and Shibutani,S. (2004) Mutagenic potential of benzo [a] pyrene-derived D NA adducts positioned in codon 273 of the human p53 gene. Biochemistry, 43, 15922-15928.
62. Denissenko,M.F., Pao,A., Pfeifer,G.P. and Tang,M. (1998) Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers. Oncogene, 16, 1241-1247.
63. Pfeifer,G.P., Denissenko,M.F., Olivier,M., Tretyakova,N., Hecht,S.S. and Hainault,P. (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene, 21, 7435-7451.
64. Fujiwara,K., Enomoto,T., Fujita,M., Kanda,T., Fuji,S., Ito,K., Wakasa,K., Ishiko,O., Ueda,M., Yamaguchi,S. et al. (2008) Alterations of the K-ras and p53 genes in tamoxifen-associated endometrial carcinoma. Oncol. Rep., 19, 1293-1298.
65. Enomoto,T., Fujita,M., Inoue,M., Nomura,T. and Shroyer,K.R. (1995) Alterations of the p53 tumor suppressor gene and activation of c-K-ras-2 protooncogene in endometrial adenocarcinoma from Colorado. Am. J. Clin. Pathol., 103, 224-230.
66. Piegorsch,W.W. and Bailer,A.J. (1994) Statistical approaches for analyzing mutational spectra: Some recommendations for categorical data. Genetics, 136, 403-416.